Skip to main content

Tyra Biosciences, Inc. (TYRA)

Sector
Healthcare
Industry
Biotechnology
Last price
$19.74
As of

Kresmion compiles this page from TYRA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Tyra Biosciences, Inc. (TYRA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-10.

As of . Source: SEC EDGAR filings for TYRA. Method and limitations.

COMPANY DOSSIER

See the full TYRA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TYRA on one page. Preview it with sample data, then open it live with a free account.

Preview the TYRA dossier

Active events for TYRA

FREE, NO ACCOUNT

Every event on TYRA, as it fires

You are seeing 5 of 14 events recorded on TYRA since 2026-05-31.

The five above landed across 3 days. The other 9 were recorded on 2 other days. 8 of the 14 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, TYRA

More data on TYRA

TYRA against its peers

TYRA's return on equity of -46.3% ranks in the 44th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.

MetricTYRAPeer medianPercentilen
Revenue FYn/a68.6Mn/a13
Gross marginn/a91.5%n/a6
Operating marginn/a-113.7%n/a13
Net marginn/a-155.0%n/a14
Return on equity-46.3%-41.5%4416
1 year-6.0%6.3%3918

Peers (20): RAPP, IMCR, SLS, QURE, PGEN, NVAX, FBRX.D, ANAB, SRPT, NBTX, KRSA, VIR, RARE, NTLA, MLYS, LBRX, DMRA, MESO, URGN, TSHA. Left out: ADRX (no annual filing), KARD (no annual filing), LYCA (no annual filing), KALV.D (no annual filing), BRVE (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (TYRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in TYRA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TYRA in the last 180 days.

Upstream: SEC EDGAR filings for TYRA

Kresmion, "Tyra Biosciences, Inc. (TYRA) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/TYRA. Upstream data: SEC EDGAR filings for TYRA.

Link to this data (HTML):

<a href="https://kresmion.com/research/TYRA">Tyra Biosciences, Inc. (TYRA) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow TYRA on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TYRA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the TYRA dossier
Share

The TYRA intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.